Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients

Completed · Phase 2

Conditions studied: End Stage Renal Disease

In brief

The purpose of this study is to determine the amount of ertapenem in the blood over time between hemodialysis session.

Key facts

Study ID

NCT02159859

Run by

Corewell Health East

People needed

7

Starts

2014-12-01

Expected to finish

2016-04-01

Last updated by the study team

2018-10-17

Who can join

Age: 18 and older, up to 88. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women age between 18 and 88 at the time of admission to Oakwood Hospital and Medical Center during January 1, 2014 or date of Institutional Review Board (IRB) approval to December 1, 2015
• Diagnosed with end stage renal disease and requires hemodialysis three times a week
• No allergy to β lactam medications
• Existing IV access for parenteral ertapenem infusion
• Willing for blood draws, at predose, 0.5, 1, 2, 6, 12 hours post-hemodialysis and pre-hemodialysis for the following hemodialysis and immediately post hemodialysis session and 1 hour post.
• No evidence of hepatic disease
• No history of alcoholism or drug abuse within pervious 2 years
• Not pregnant

You may not qualify if…

• History of any form of epilepsy, seizure or convulsion
• Currently taking any forms of valproic acid or divalproex sodium for treatment of any disease states
• Currently taking probenecid
• Current Clostridium difficile (C. diff.) infection, defined as 30 days prior to day-1 of receiving ertapenem for this study
• Currently receiving any antimicrobial agents for prophylaxis or treatment

Where it is running

• Oakwood Hospital - Dearborn — Dearborn, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.